S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
Could trawler cams help save world's dwindling fish stocks?
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Southwest Airlines brings back dividend as travel rebounds
3 Dividend Kings With Royally Good Upside
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
Could trawler cams help save world's dwindling fish stocks?
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Southwest Airlines brings back dividend as travel rebounds
3 Dividend Kings With Royally Good Upside
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
Could trawler cams help save world's dwindling fish stocks?
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Southwest Airlines brings back dividend as travel rebounds
3 Dividend Kings With Royally Good Upside
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
Could trawler cams help save world's dwindling fish stocks?
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Southwest Airlines brings back dividend as travel rebounds
3 Dividend Kings With Royally Good Upside
NASDAQ:CLRB

Cellectar Biosciences - CLRB Stock Forecast, Price & News

$1.75
0.00 (0.00%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.59
$1.85
50-Day Range
$1.75
$3.46
52-Week Range
$1.59
$7.90
Volume
92,686 shs
Average Volume
31,605 shs
Market Capitalization
$16.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67

Cellectar Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
338.1% Upside
$7.67 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.49) to ($2.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

397th out of 1,027 stocks

Pharmaceutical Preparations Industry

168th out of 503 stocks

CLRB stock logo

About Cellectar Biosciences (NASDAQ:CLRB) Stock

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Stock News Headlines

Recap: Cellectar Biosciences Q3 Earnings
Cellectar Decreases in Price on Private Placement
Cellectar Dips on Grant
Cellectar Dips on Q2 Figures
Cellectar Announces Stock Consolidation
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences GAAP EPS of -$0.10 in-line
See More Headlines
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Company Calendar

Last Earnings
11/07/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/20/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLRB
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.67
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+338.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-24,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.18 per share

Miscellaneous

Free Float
9,122,000
Market Cap
$16.43 million
Optionable
Not Optionable
Beta
1.18

Key Executives

  • Mr. James V. Caruso (Age 63)
    Pres, CEO & Director
    Comp: $679.25k
  • Mr. Jarrod Longcor (Age 49)
    Chief Operating Officer
    Comp: $477.45k
  • Mr. Chad J. Kolean CPA (Age 58)
    CPA, CFO & Sec.













CLRB Stock - Frequently Asked Questions

Should I buy or sell Cellectar Biosciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings
or view top-rated stocks.

What is Cellectar Biosciences' stock price forecast for 2023?

2 analysts have issued 12-month price targets for Cellectar Biosciences' shares. Their CLRB share price forecasts range from $4.00 to $12.00. On average, they expect the company's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 338.1% from the stock's current price.
View analysts price targets for CLRB
or view top-rated stocks among Wall Street analysts.

How have CLRB shares performed in 2022?

Cellectar Biosciences' stock was trading at $6.64 at the beginning of the year. Since then, CLRB shares have decreased by 73.6% and is now trading at $1.75.
View the best growth stocks for 2022 here
.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 8,100 shares, a decrease of 16.5% from the October 31st total of 9,700 shares. Based on an average daily volume of 36,400 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the company's stock are short sold.
View Cellectar Biosciences' Short Interest
.

When is Cellectar Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our CLRB earnings forecast
.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) announced its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?

Cellectar Biosciences's stock reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.87%), BlackRock Inc. (0.61%), Worth Venture Partners LLC (0.44%), Maven Securities LTD (0.27%), Maven Securities LTD (0.27%) and ACT Capital Management LLC (0.36%). Insiders that own company stock include Dov Elefant, James V Caruso, Jarrod Longcor and Stephen A Hill.
View institutional ownership trends
.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $1.75.

How much money does Cellectar Biosciences make?

Cellectar Biosciences (NASDAQ:CLRB) has a market capitalization of $16.42 million. The biopharmaceutical company earns $-24,120,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The official website for the company is www.cellectar.com. The biopharmaceutical company can be reached via phone at (608) 441-8120, via email at ir@cellectar.com, or via fax at 608-441-8121.

This page (NASDAQ:CLRB) was last updated on 12/8/2022 by MarketBeat.com Staff